Different roles of matrix metalloproteinases-2 and -9 after human ischaemic stroke

Neurological Sciences

Volumn 28, Issue 4, 2007, Pages 165-170

  Lucivero, V ^a   Prontera, M ^a   Mezzapesa, D M ^a   Petruzzellis, M ^a   Sancilio, M ^a   Tinelli, A ^a   Di Noia, D ^a   Ruggieri, M ^a   Federico, Francesco ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Acute ischaemic stroke; Matrix metalloproteinases

Indexed keywords

ACETYLSALICYLIC ACID; GELATINASE A; GELATINASE B; LOW MOLECULAR WEIGHT HEPARIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; FEMALE; HUMAN; MALE; PROGNOSIS; PROTEIN BLOOD LEVEL; SYMPTOMATOLOGY; VENOUS THROMBOEMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; STROKE; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 34547959390     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10072-007-0814-0     Document Type: Article

References (25)

1. Rosenberg GA (2002) Matrix metalloproteinases in neuroinflammation. Glia 39:279-291
2. Fatar M, Stroick M, Griebe M, Hennerici M (2005) Matrix metalloproteinases in cerebrovascular diseases. Cerebrovasc Dis 20:141-151
3. Rosenberg GA, Estrada EY, Dencoff JE (1998) Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke 29:2189-2195
4. Nelson R (2005) Novel MMP inhibitor has potential for treatment of stroke. Lancet Neurol 4:530
5. Lapchak PA, Araujo DM (2001) Reducing bleeding complications after thrombolytic therapy for stroke: Clinical potential of metalloproteinase inhibitors and spin trap agents. CNS Drugs 15:819-829
6. Zhao BQ, Wang S, Kim HY et al (2006) Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat Med 12:441-445
7. Cunningham LA, Wetzel M, Rosenberg GA (2005) Multiple roles for MMPs and TIMPs in cerebral ischemia. Glia 50:329-339
8. Bamford J, Sandercock P, Dennis M et al (1991) Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 337:1521-1526 1521-1526
9. Adams HP Jr, Bendixen BH, Kappelle LJ et al (1993) Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24:35-41
10. Brott T, Adams HP Jr, Olinger CP et al (1989) Measurements of acute cerebral infarction: A clinical examination scale. Stroke 20:864-870.
11. Van Swieten JC, Koudstaal PJ, Visser MC et al (1988) Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19:604-607
12. Asahi M, Wang X, Mori T et al (2001) Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci 21:7724-7732
13. Montaner J, Alvarez-Sabin J, Molina C et al (2001) Matrix metalloproteinase expression after human cardioembolic stroke: Temporal profile and relation to neurological impairment. Stroke 32:1759-1766
14. Horstmann S, Kalb P, Koziol J et al (2003) Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies. Stroke 34:2165-2170
15. Montaner J, Molina CA, Monasterio J et al (2003) Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 107:598-603
16. Montaner J, Alvarez-Sabin J, Molina CA et al (2001) Matrix metalloproteinase expression is related to hemorrhagic transformation after cardioembolic stroke. Stroke 32:2762-2767
17. Kim YS, Lee KY, Koh SH et al (2006) The role of matrix metalloproteinase 9 in early neurological worsening of acute lacunar infarction. Eur Neurol 55:11-15
18. Montaner J, Rovira A, Molina CA et al (2003) Plasmatic level of neuroinflammatory markers predict the extent of diffusion-weighted image lesions in hyperacute stroke. J Cereb Blood Flow Metab 23:1403-1407
19. Rosell A, Alvarez-Sabin J, Arenillas JF et al (2005) A matrix metalloproteinase protein array reveals a strong relation between MMP-9 and MMP-13 with diffusion-weighted image lesion increase in human stroke. Stroke 36:1415-1420
20. Castellanos M, Leira R, Serena J, Davalos A (2003) Plasma metalloprotinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke 34:40-46
21. Vukasovic I, Tesija-Kuna A, Topic E et al (2006) Matrix metalloproteinases and their inhibitors in different acute stroke subtypes. Clin Chem Lab Med 44:428-434
22. Clark AW, Krekoski CA, Bou SS et al (1997) Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia. Neurosci Lett 238:53-56
23. Jourquin J, Tremblay E, Decanis N et al (2003) Neuronal activity-dependent increase of net matrix metalloproteinase activity is associated with MMP-9 neurotoxicity after kainate. Eur J Neurosci 18:1507-1517
24. Visse R, Nagase H (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure, function, and biochemistry. Circ Res 92:827-839
25. Jian Liu K, Rosenberg GA (2005) Matrix metalloproteinases and free radicals in cerebral ischemia. Free Radic Biol Med 39:71-80